The role of human papillomavirus (HPV) in sinonasal inverted papillomas (IPs) is controversial. Determining the prevalence of HPV infection and its impact on the molecular biology of these tumors is critical to characterizing its role in the pathogenesis of IPs.
S
inonasal inverted papillomas (IPs) are benign but locally aggressive tumors. 1 With an incidence between 0.74 and 1.5 cases per 100,000 persons per year, IPs account for 0.4% to 4.7% of all sinonasal neoplasms. 2, 3 IPs are reported to have a substantial recurrence rate of up to 32%, and degenerate into or simultaneously harbor squamous cell carcinoma (SCC) in 15% of cases. 3, 4 The pathogenesis and etiology of IPs is still unclear. Human papillomavirus (HPV) has been implicated repeatedly in development of IPs, but the detection rates vary widely in the literature with a range of 0% to 72% and an average of about 25%. 3, 5 HPV infection plays an important role in the clinical evolution of IPs. The reported detection rate of HPV is increased in IPs with high-grade dysplasia and carcinoma when compared to IPs with no dysplasia or mild dysplasia. Similarly, the HPV detection rate is higher in the IPs that recur. [5] [6] [7] HPV types detected in IPs are most commonly low-risk types HPV 6/11, and high-risk types HPV 16/18. Of these subtypes, HPV 6/11 are more common than HPV 16/18, with an overall unadjusted ratio of lowrisk HPV to high-risk HPV of 2.8:1. When dysplasia or SCC is present, HPV typing reveals a higher proportion of high-risk types. 5, 8 The oncogenic mechanisms of high-risk HPV in head and neck cancer have been extensively studied and described. The role of these mechanisms in the pathogenesis of IPs is still not clear. Previous studies have provided evidence of the presence of HPV 6 E6 and E7 transcripts in IPs. 9 E6 has many biological activities that can lead to cellular transformation. One of the most studied mechanisms of this oncoprotein is its capability to cause the ubiquitination of p53. The ubiquitin-conjugated p53 is exported from the nucleus and degraded by proteosomes. 10, 11 A study of IPs suggests that this E6-mediated mechanism takes place in these tumors, in that the levels of p53 and p21 are decreased in IPs with high-risk HPV compared to the IPs without HPV infection. 7 In contrast, in a previous study, we reported that regardless of the HPV status high expression of p53 correlates with the presence of carcinoma in IPs. 12 Because decreased p53 levels appear to be a hallmark of high-risk HPV-induced tumors, this study's results do not concur with the hypothesis that malignant transformation of IPs is an HPV-driven event.
HPV is also reported to increase the expression of epidermal growth factor receptor (EGFR) by a direct increment in its transcription, mediated by E6 (Akerman et al. 13 ), or by recycling of EGFR mediated by E5. 14, 15 In IPs, increased expression of EGFR correlates with high-grade dysplasia and malignancy. 16, 17 The HPV protein E7 is able to bind to the tumor suppressor protein Rb and decrease its activity. This depressed Rb activity is independent from its normal regulatory proteins cyclin D1 and p16. The transcription factor E2F, which is normally inhibited by Rb, drives expression of genes that cause cell-cycle progression from G1 to S phase. The normal feedback inhibitory protein of this pathway p16INK4a is typically overexpressed in the presence of HPV transforming proteins. Overexpression of p16 has proven to be a specific and sensitive marker for HPV involvement in squamous oropharyngeal cancer. 18, 19 However, in IPs, p16 could not be established as a marker of HPV infection and low expression of p16 has been correlated with malignancy in IPs. 12, 20 The absence of an elevated p16 expression in IPs harboring cancer does not support a model where high-risk HPV E7 protein is a driver of malignant transformation.
Recent studies in head and neck cancer have showed high-risk HPV integration to the cellular genome with consequent disruption of important cellular regulatory pathways. 21 Integration of low-risk HPV has also been implicated in malignant progression of laryngeal papillomatosis. 22 Using the E7/E5 transcript ratio as an indirect indicator of HPV integration, 1 study suggested the integration of HPV in IPs with synchronic SCC. 23 The purpose of this study is to describe the clinical and biological role of HPV infection in a group of 90 patients with IPs. We study the mechanisms of HPV pathogenesis in IPs using a detection of integrated papillomavirus sequences by ligation-mediated polymerase chain reaction (DIPS-PCR) assay modified for HPV 11 and complement this data with previously published immunohistochemistry for p53, p16, EGFR, and cyclin D1. 12 
Patients and methods
The study was approved by the University of Michigan Institutional Review Board (IRB). Patients with IPs were identified by searching the University of Michigan Pathology Archive from the year 1996 to 2011. Other types of sinonasal papillomas were excluded (ie, fungiform and oncocytic/cylindrical papillomas). IPs with dysplasia or carcinoma were included in the study.
P53, p16, EGFR, and cyclin D1 immunohistochemistry
The p53, p16, EGFR, and cyclin D1 immunohistochemistry performed on these specimens has been described and published. 12 A tissue microarray (TMA) was constructed, deparaffinized, and rehydrated. The immunohistochemistry staining was then performed. The tumor area stained was scored as a proportion on a scale of 1 to 4 (grade 1 = <5%; grade 2 = 5% to 20%; grade 3 = 21% to 50%; grade 4 = >50%). The intensity of staining was also scored on a scale of 1 to 4 (1 = no staining; 2 = low intensity; 3 = moderate intensity; 4 = high intensity). Tumors with a staining intensity score 2 or higher were considered to stain positive for the biomarker.
DNA extraction from paraffin-embedded IPs
A pathologist marked representative areas of tumor in the paraffin blocks. Cores were taken from the marked areas, deparaffinized with xylene, and digested with proteinase K. DNA quantity and quality were corroborated with an ultraviolet (UV)-visible light spectrophotometer using a NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE).
HPV detection
The PGMY 09/11 L1 consensus primer set was used to detect HPV as described. 24 The isolated DNA from each sample was amplified in the presence of 4 mM MgCl 2 , 200 μM dNTP mix, 0.2 μM PGMY09/11 primer mix, 0.05 μM β-globin primers (PCO4 and GH20), 1× PCR Buffer II, and 7.5 U of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ). Amplification was performed in an Eppendorf Mastercycler Gradient thermal cycler (Eppendorf Scientific, Hamburg, Germany) at 95°C for 9 minutes then 40 cycles of 95°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute. This was followed by a final extension at 72°C for 5 minutes, and the amplification reaction mixtures were stored at 4°C. For the samples that showed an L1 PCR product, a new PGMY 09/11 PCR reaction was performed excluding the β-globin primers. The DNA was purified using the QIAquick PCR Purification Kit as described by the manufacturer (Qiagen Sciences, Germantown, MD) and Sanger sequenced in the University of Michigan Genomics Core. The sequences were aligned with known HPV types using the NCBI Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
All samples were also analyzed with a second sensitive method, HPV PCR-MassArray, for the detection and identification of high-risk HPV types as described. 25 
HPV 11 DIPS-PCR
To determine the physical state and site of integration of high-risk HPV 16, a DIPS-PCR-based method was used. [26] [27] [28] We modified this method and designed a new set of primers that will cover the entire low-risk HPV 11 genome (Table 1 , Fig. 1 ). The genomic DNA (800 ng) was digested using 20 units of Taqα1 (New England Biolabs, Ipswich, MA) in a volume of 20 μL at 65°C overnight in an Eppendorf Mastercycler Gradient thermal cycler. The reaction was heat-inactivated at 80°C for 20 minutes. A double-stranded annealed adapter was then ligated to the digested DNA. The adapter consists of a long strand (5 -gggccatcagtcagcagtcgtagccggatccagacttacacgttg-3 ) and a short strand (5 -PO4-cgcaacgtgtaagtctg-NH2-3 ). The ligation was performed using 3 units of T4 DNA Ligase (Promega Corporation, WI), 50 pmol annealed adapter, and the digested DNA in a 20-μL reaction at 14°C overnight. The product was then diluted to 40 μL. A first linear PCR reaction was performed using 2 μL of the previously digested and ligated DNA, 1× PCR buffer, The reaction parameters were an initial denaturation at 96°C for 2 minutes, then 30 cycles of 96°C denaturation of 30 seconds, 62°C primer annealing for 30 seconds, and 72°C primer extension for 3 minutes, followed by a final 72°C extension for 7 minutes. The PCR products were analyzed using electrophoresis in a 2% agarose gel. The resulting bands were cut from the gel and purified using the QIAquick Gel Extraction Kit as described by manufacturer (QIAGEN Sciences, MD). The purified DNA was sequenced, and the integration sequences were detected using the NCBI Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Statistical analysis
Mean percentage staining by tumor surface area for HPVpositive and HPV-negative IPs were compared using 2-tailed t test. Staining proportions were compared using a 2-tailed Z test for proportions. All p values <0.05 were considered to be statistically significant, and values between 0.05 and 0.10 as indicating a statistical trend.
Results
A total of 162 paraffin-embedded specimens from 147 patients were collected and studied. Twenty-two specimens (13.6%) harbored carcinoma. One hundred and eleven (111) patients (75.5%) were male. The population characteristics have been described.
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HPV incidence and types DNA was successfully extracted for analysis from 112/162 IP samples corresponding to 90 patients. HPV detection was carried out using the PGMY PCR-based detection method. 24 Coamplification of β-globin was used as a reaction-positive control. Eleven (12.2%) of the 90 patient tumors studied were HPV-positive (Table 2. ). One patient with an HPV-positive tumor had 2 specimens collected 1 year apart. Both samples were positive for the same HPV type, and the second sample contained SCC. From the 11 HPV-positive tumors, 9 contained HPV 11, one contained HPV 6, and one contained HPV 27. There were no high-risk HPV types detected in this patient cohort as assessed by the PGMY L1 assay and confirmed by HPV PCR-MassArray.
HPV status and expression of EGFR, p16, p53, and cyclin D1 immunohistochemistry
The HPV status was compared to p53, p16, EGFR, and cyclin D1 protein levels (Tables 3 and 4 ). Immunohistochemistry data was available for 77 tumors, 8 HPV-positive, and 69 HPV-negative. HPV-infected IPs stained for EGFR in 87.5% (7/8) tumors, whereas only 58% (40/69) of HPVnegative IPs stained for EGFR. This difference was not statistically significant (p = 0.11). However, when the mean percentage area of the tumor stained for EGFR was considered, HPV-positive tumors had increased staining compared to the HPV-negative tumors, with a stained mean percentage area of 56.2% vs 23.6%, respectively (p = 0.009). Positive p16 immunohistochemistry was observed in 50% (4/8) of the HPV-infected IPs vs 71% (49/69) of HPVnegative IPs although the difference was not significant (p = 0.22). The tumor mean percentage area stained for p16 was 11.7% vs 10.3% for the HPV-positive and HPV-negative tumor, respectively (p = 0.858).
Positive staining for p53 was present in 62.5% (5/8) of HPV-positive specimens vs 50.7% (35/69) of HPV-negative samples (p = 0.52). The mean area stained for p53 was 11% for HPV-infected specimens and 8.5% for HPV-free specimens (p = 0.612).
Cyclin D1 immunohistochemistry was positive in 75% (6/8) of HPV-infected and 80% (57/71) of HPV-negative samples (p = 0.72). Tumor mean percentage areas were 17.08% and 17.23% for HPV-positive and HPV-negative samples, respectively (p = 0.983).
HPV in cancer progression and papilloma recurrence
Progression of IPs to SCC occurred in 36.36% (4/11) HPVpositive patients, and 14.1% (11/78) HPV-negative patients (p = 0.064). All HPV-positive patients who presented with SCC had HPV 11 infection. Also, IPs recurred in 63.64% (7/11) of HPV-positive vs 45.33% (34/75) of HPV-negative lesions (p = 0.256).
Integration of HPV 11 in inverted papillomas that progressed to SCC
From the HPV 11-positive specimens, only 3 had sufficient DNA for HPV 11 DIPS-PCR analysis. Two of the specimens were from the same patient. The first specimen was an IP, and 1 year later a specimen containing SCC was obtained from this patient. The specimen with SCC showed that HPV 11 had 1 integration site in an intergenic region of chromosome 5q31. The HPV 11 insertional breakpoint was found in L1. The IP obtained 1 year earlier from the same patient did not show any HPV integration events. The third specimen analyzed with HPV 11 DIPS-PCR is a SCC that contained 3 integration events. The integrations were found in intergenic regions of chromosomes 18q11.1, 5p13.2, and 2p22.1. The HPV integration breakpoints were in E6, L1, and L1, respectively.
Discussion
Many etiological agents have been proposed for IPs. HPV has been proposed as the main etiological factor. However, in our dataset only a low proportion of IPs, 11 in 90 (12.2%) of our patients, harbor HPV in their lesions. A recent meta-analysis reported that HPV has been found in 25% of IPs, with high variability between studies. 5 The low HPV presence suggests that it is only 1 of the etiological agents for IPs.
Interestingly, we did not find any high-risk HPVs in the IPs studied. We used 2 robust assays, 1 based on consensus L1 PCR primers PGMY 09/11 (Gravitt et al. 24 ) and the HPV multiplex PCR MassArray analysis based on the viral E6 region. 25 Even without the presence of high-risk HPVs, we noted a trend for low-risk HPV-positive samples to have a greater proclivity for malignant progression to invasive squamous carcinoma than HPV-negative samples IPs. However, this trend was not statistically significant. This observed tendency to progression was further studied in a meta-analysis and proved that HPV-positive samples progress more frequently than HPV-negative IPs. They also found that HPV-positive IPs have a higher recurrence rate than the HPV-negative tumors, a correlation that was not found in our study. This discrepancy could be caused by our lower statistical power due to our low number of HPVpositive cases, or by a difference in the biological activity of high-risk HPV vs low-risk HPV. In contrast to our study, in the cited meta-analysis high-risk HPV 16/18 were detected in 3.5% (0% to 33.3%) IPs with no or low-grade dysplasia and 33.8% (0% to 100%) IPs with SCC. 5 The role of low-risk HPV as a prognostic marker has not been confirmed.
The variability of HPV detection between studies can be a reflection of different patient characteristics and may also include varying levels of HPV detection expertise. Sample sets that include a higher number of dysplastic and malignant lesions and higher numbers of recurrent cases are more likely to have higher HPV incidence. 5, 30 Laboratories with greater experience with HPV detection and strong quality control measures may have more accurate HPV detection rates and lower false-positive rates. [31] [32] [33] The oncogenic mechanisms of HPV have been studied extensively. Most high-risk HPV-induced cancers are driven by the viral oncogenes. HPV-positive tumor cell lines are dependent on E6 and E7 expression for proliferation and survival. [34] [35] [36] Whereas most attention has been given to these HPV-mediated effects on the p53 and pRb pathways, this study's results indicate the importance of HPV-induced upregulation of EGFR expression. [13] [14] [15] EGFR mean percentage area staining was the only biomarker that was significantly increased in our low-risk HPV-positive set compared to the HPV-negative cases. Cyclin D1, p16, and p53 expression showed no difference between the 2 groups. These results provide a rationale to test EGFR inhibitors for the treatment of low-risk HPV-positive IPs. The Radiotherapy plus Cetuximab multicenter study of locoregionally advanced head and neck cancer reported by Bonner et al. 37 revealed that overall survival was only modestly increased in the radiotherapy plus cetuximab arm over radiation alone. However, in a subsequent follow-up at 5 years, the survival advantage for the cetuximab arm became significant. In subgroup analysis, male patients less than 65 years old, treated in the United States with T1-3, N1-N3 oropharynx cancer exhibited the greatest benefit from the addition of cetuximab to the treatment. 37 This effect could be attributed to the presence of HPV, considering that it has been established that HPV is now the main etiologic agent for oropharynx cancer, 38 whereas in head and neck cancers at other sites the role of HPV is not as significant. 25, 39 Furthermore, Kies et al. 40 treated oropharynx cancer with paclitaxel and carboplatin with and without cetuximab and found that survival was better for the HPV-positive patients in the cetuximab group. Thus, it is conceivable that there may be a role for anti-EGFR treatment in the management of HPV-related sinonasal tumors.
Recent studies indicate that integration of high-risk HPV in human genomic DNA from SCC can disrupt important cell regulatory genes. 21 Here we designed a DIPS-PCR assay modified to detect the integration of low-risk HPV 11 into human genomic DNA. Interestingly, we found that all of the low-risk HPV 11 integrations were in intergenic DNA regions and did not directly alter the sequence of any gene. This is in contrast to gene disruption by intragenic high-risk HPV integration as a secondary factor in oncogenesis. 21 However, Schmitz et al. 41 observed that in a large number of cervical carcinomas, intergenic integration also frequently occurs in the vicinity of microRNAs, which could also alter host cell gene expression and foster malignant progression. In their work, Schmitz et al. 41 noted that the integration process of high-risk HPVs was directed by cellular homologies with the viral E5 and L2 sequences. These homologies targeted 9 genes that were commonly disrupted. 41 In this study we found that the low-risk HPV 11 was frequently integrated in the L1 sequence. This finding suggests that integration of HPV 11 is also a targeted process, but more studies are necessary to confirm this.
In 1 subject, an initial IP sample and a second sample that was obtained when the lesion progressed to SCC were available for evaluation. There was no HPV 11 integration present in the IP sample, although an HPV 11 intergenic integration was present in the SCC sample 1 year later. Huebbers et al. 22 reported similar findings in a case of a young woman with HPV 6-positive recurrent respiratory papilloma that progressed to SCC. HPV integration was not found in 2 respiratory papilloma specimens but in the later SCC sample from this patient, HPV 6 was integrated into aldo-keto reductase 1C3, resulting in gene disruption and loss of function. 22 These results indicate that HPV integration occurs concurrently with malignant transformation, but it is still unclear whether the viral integration is a driver of malignancy or a consequence of genomic instability caused by HPV-independent mechanisms.
Conclusion
The low frequency of HPV in IPs in this series suggests that this virus is not a major etiological agent for this disease. We identified a trend to progression to carcinoma in the presence of HPV, an observation that has been confirmed in a recent meta-analysis. 4 EGFR was the only biomarker tested that was overexpressed in low-risk HPV positive samples, suggesting that anti-EGFR therapy could have a role in reducing risk of progression in HPV-positive IPs. Intriguingly, our results suggest that integration of HPV into the cellular genomic DNA occurs with malignant transformation, but this requires further study. It is unclear if viral integration is the cause or a consequence of malignancy.
